Gilead Q2 FY26 loss per share widens to $(8.45); revenue rises 10% to $7.8 billion
Reuters2026/08/04 20:09- Gilead posted Q2 2026 revenue up 10% to USD 7.8 billion, while diluted EPS swung to a loss of USD 8.45.
- Acquired in-process R&D charges totaled USD 11.2 billion, tied mainly to the Arcellx, Tubulis and Ouro Medicines acquisitions.
- HIV sales rose 12% to USD 5.7 billion, with Biktarvy up 7% to USD 3.8 billion; Descovy jumped 48% to USD 967 million.
- Trodelvy sales climbed 26% to USD 457 million, while Veklury revenue fell 81% to USD 23 million; cell therapy slid 14% to USD 417 million.
- FY 2026 product sales guidance edged up to USD 30.1 billion–USD 30.4 billion, while diluted loss per share outlook widened to USD 3.75–USD 3.4.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma
GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.
Alphabet's Waymo, Local Partners Plan 2027 Tokyo Autonomous Taxi Launch
Germany's DAX 40 fell to 25,200 points, down 0.8% in 24 hours
Borr Drilling Divests Mexican Oil Drilling Joint Ventures
Crypto prices
More
